AUTHORS
Daniel J Vail, PhD, Babal Kant Jha, PhD2, Dongxu Jiang, PhD3, Valeria Visconte, PhD4, Jaroslaw P. Maciejewski, MD, PhD, FACP5, Thomas Laframboise, PhD6
AFFILIATIONS
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
ABSTRACT
Monosomy 7 and deletion 7q (-7/del(7q)) are recurrent adverse cytogenetic lesions across leukemias, with particular relevance to pediatric and bone marrow failure–associated disease1,2. Their association with aggressive disease and limited therapeutic options underscores the need for lesion-specific treatment strategies. Large chromosomal deletions may create selective vulnerabilities by reducing the dosage of multiple genes and increasing dependence on compensatory pathways required to maintain leukemic-cell survival. We integrated bulk RNA sequencing and single-cell RNA sequencing (scRNA-seq) with functional gene perturbation using CRISPR technology to identify and prioritize candidate synthetic-lethal genes (SLGs) in -7/del(7q) AML.
We applied two complementary strategies to identify dependencies associated with chromosome 7 loss. First, using bulk RNA-seq from 107 AML samples, including 29 -7/del(7q) cases and 78 chromosome 7-diploid cases, we tested each chromosome 7q gene against genes throughout the transcriptome to identify compensatory expression associated with its deletion3. This analysis identified recurrent upregulation of BEND4, NPDC1, KRT18, and TANC1 in association with loss of multiple chromosome 7q genes. Second, we identified chromosome 7 genes whose expression was preserved or increased despite hemizygous deletion, potentially reflecting dosage-sensitive dependencies maintained by the remaining allele.
We functionally evaluated selected candidates using CRISPR/Cas9 disruption in KG-1 AML cells, which harbor monosomy 7. Disruption of BEND4 or NPDC1 consistently impaired leukemic-cell expansion, prolonging doubling time by approximately 16 and 10 hours, respectively. These results identify BEND4 and NPDC1 as functional dependencies in a monosomy 7 cellular context.
To determine the cellular distribution and potential therapeutic selectivity of candidate SLGs, we analyzed scRNA-seq from 29 AML patients, including 17 -7/del(7q) and 12 normal-karyotype cases. Patient-level pseudobulk analysis localized the most prominent -7/del(7q)-associated expression differences to hematopoietic stem and progenitor populations. BEND4 and CCDC85C were strongly enriched in -7/del(7q) progenitor populations while demonstrating little to no expression in corresponding healthy hematopoietic progenitors.
Projection of AML cells onto recurrent aberrant differentiation patterns further demonstrated that candidate dependencies were maintained across biologically distinct -7/del(7q) disease states. NPDC1 and PAWR showed the strongest -7/del(7q)-associated expression differences in HSC/MPP-like AML and were also enriched in intermediate/pDC and early-myeloid transcriptional patterns. Together, these three patterns accounted for 64.5% of -7/del(7q) cases. BEND4, CKB, CCDC85C, and KRT18 showed additional enrichment across these predominant patterns, with candidate SLG expression generally highest in early progenitor-like populations.
Finally, analysis of paired diagnosis and relapse samples demonstrated persistent expression of BEND4, NPDC1, and PAWR across early progenitor populations in a -7/del(7q) relapse case. NPDC1 expression also increased in early progenitor populations following relapse in multiple normal-karyotype AML cases, suggesting that dependency on NPDC1-associated programs may extend beyond chromosome 7 loss in refractory disease.
Collectively, these analyses define a set of candidate therapeutic dependencies created or reinforced by ‑7/del(7q). Integration of functional validation, malignant-cell-state specificity, expression in normal hematopoiesis, and persistence at relapse prioritizes BEND4, NPDC1, PAWR, and CCDC85C for further investigation. BEND4 emerges as a particularly compelling candidate based on its functional requirement in monosomy 7 AML cells, selective expression in -7/del(7q) progenitor-like blasts, and minimal expression in normal hematopoiesis.
DISCLOSURES
Daniel J Vail, PhD: No relevant conflicts of interest to declare.